Drugs / Molibresib
Molibresib
also known as
GSK525762 · Bet inhibitor gsk525762 · GSK-525762A · GSK525762 Besylate · GSK525762C · I-BET 762 · molibresib besylate
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials · 1 missed | ||||||
| Phase 1 | NCT03925428 | Sep 2020 | T-cell non-Hodgkin lymphoma, adult lymphoma, aggressive B-cell non-Hodgkin lymphoma, pancreatic adenocarcinoma +1 | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT02964507 | Sep 2019 → Sep 2020 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT03150056 | Jul 2017 → Jul 2020 | cancer | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02706535 | May 2016 → Jan 2017 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01587703 | Mar 2012 → Apr 2018 | nut midline carcinoma | GlaxoSmithKline | Completed | Missed primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04116359 | Sep 2020 | nut midline carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03266159 | Nov 2017 → Aug 2020 | cancer | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT01943851 | May 2014 → Apr 2020 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03702036 | — | cancer | GlaxoSmithKline | No longer available | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | molibresib | “Molibresib (GSK525762) is an investigational, orally bioavailable, small-molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors.” PMID 33955700 ↗ Jun 2021 |
| Known as | Bet inhibitor gsk525762 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1232461 ↗ |
| Known as | GSK-525762A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1232461 ↗ |
| Known as | GSK525762 | “Molibresib (GSK525762) is an investigational, orally bioavailable, small-molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors.” PMID 33955700 ↗ Jun 2021 |
| Known as | GSK525762 Besylate | “GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings.” NCT03266159 ↗ |
| Known as | GSK525762C | “This phase I trial studies the side effects and best dose of GSK525762C (molibresib besylate) and entinostat in treating patients with solid tumors or lymphomas that have...” NCT03925428 ↗ |
| Known as | I-BET 762 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1232461 ↗ |
| Known as | molibresib besylate | “This phase I trial studies the side effects and best dose of GSK525762C (molibresib besylate) and entinostat in treating patients with solid tumors or lymphomas that have...” NCT03925428 ↗ |
| Action | Inhibit | “Molibresib (GSK525762) is an investigational, orally bioavailable, small-molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors.” PMID 33955700 ↗ Jun 2021 |
| Modality | Small molecule | “Molibresib (GSK525762) is an investigational, orally bioavailable, small-molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors.” PMID 33955700 ↗ Jun 2021 |
| Route | Oral | “after oral administration of GSK525762” NCT01587703 ↗ |